Oragenics reports no serious adverse events yet in ONP-002 concussion trial
The July update activates all three Australian sites and clears a safety bar, but leaves the symptom-reduction result that defines the Phase 2a trial for a Q4 2026 readout.
Executive Summary
- Oragenics completed site activation across its Australian concussion trial and disclosed an interim safety update showing no serious adverse events, while the result that will determine whether ONP-002 works remains outstanding.
- Concussion and mild traumatic brain injury have no approved pharmacological treatment, so a positive symptom-reduction signal would address an unmet need in a field where no other clinical-stage program targets the same mechanism.
- The company is also advancing a parallel regulatory track, having asked the FDA for guidance on U.S. development ahead of a planned IND, but that path depends on the same trial data still to come.
- The safety finding and the operational milestone are informative on their own terms; neither substitutes for the primary symptom endpoint, which is the fact that will actually move the program forward.
The update
Oragenics said on July 7, 2026 that all three planned sites in its Australian Phase 2a trial of ONP-002, Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital, are now active and enrolling, with Royal Adelaide Hospital's Research Governance Office approval on June 29, 2026 completing the site network. Alfred Health enrolled its first participant on June 21, 2026. The company reported zero serious adverse events across all subjects dosed to date. OragenicsOragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now ...Jul 7, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial tests
The Phase 2a study (NCT06870240) is a randomized, double-blind, placebo-controlled trial enrolling adults aged 18 to 55 with mild traumatic brain injury, targeting 40 participants split between ONP-002 and placebo arms. The registered primary endpoint is patient symptom reporting. ONP-002 is delivered intranasally, designed to reach the brain directly rather than through infusion or oral dosing, and the company describes it as a first-in-class approach for concussion, a condition with no FDA-approved pharmacological treatment. No serious adverse events reported to date is a safety signal; it says nothing about whether the drug reduced concussion symptoms against placebo, which is the question the primary endpoint was built to answer. NCT06870240+1A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain InjuryNCT06870240Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now ...Jul 7, 2026
Timing
Oragenics has held Q4 2026 as its target data-readout window since at least February 2026, repeating that guidance in the July update. The trial's registered primary completion date is January 1, 2026, and the study remained listed as not yet recruiting in its registry record as of the disclosed metadata, a status that predates the site-activation and dosing progress the company has since reported. Enrollment held at its 40-participant target with no change in size, which the trial's own operational baseline treats as a routine, unremarkable figure. Oragenics+2Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage ...Feb 9, 2026Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now ...Jul 7, 2026A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain InjuryNCT06870240
Regulatory track
Oragenics submitted a Type B meeting request to the FDA on June 26, 2026 to seek guidance on its planned U.S. development program for ONP-002, ahead of an IND submission still targeted for the fourth quarter of 2026. Any Phase 2b trials in the U.S. depend on that IND clearing first. Concussion and mTBI carry no FDA-approved pharmacological treatment, and none of the competing programs identified in the trial's indication, propranolol, lisdexamfetamine, inosine, ronopterin, aerobic exercise, mesenchymal stem cells, amantadine, and NE3107, share ONP-002's intranasal neurosteroid mechanism, leaving the asset without a direct comparator in the current competitive field. OragenicsOragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now ...Jul 7, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.